Fanaroff AC, Peterson ED, Kaltenbach LA, et al. - Researchers investigated if an increased patient persistence in receiving other secondary prevention cardiovascular medications can be obtained by offering copayment reduction for P2Y₁₂ inhibitors. In this secondary analysis of the Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS) cluster-randomized trial, they analyzed data from 287 hospitals that registered patients between June 2015 and September 2016. This analysis included patients hospitalized with acute myocardial infarction. In hospitals, wherein, the intervention was implemented, patients vouchers that waived copayments for P2Y₁₂ inhibitors fills for 1 year were granted. No study vouchers were offered by hospitals randomized to usual care. They found that there was a significantly increased patient persistence in taking not only P2Y₁₂ inhibitors but also in taking β-blockers and statins, as a result of providing copayment assistance for P2Y₁₂ inhibitors. However, no such benefit on the receipt of angiotensin-converting enzyme inhibitors or angiotensin II–receptor blockers was evident in relation to this intervention.